Merck's 2025 Results: Oncology Strength & Pipeline Progress

SEC 8-K Filing Notice

Company: Merck & Co., Inc. (MRK) Filing Date: 2026-02-03 Accession Number: 0001104659-26-009495

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

Merck (MRK) reported its Q4 and full-year 2025 financial results, highlighting strong performance in oncology (driven by KEYTRUDA), animal health, and increasing contributions from newer products like WINREVAIR and CAPVAXIVE. Full-year sales reached $65.0 billion, a 1% increase (2% ex-FX). The company also touted significant pipeline advancements, including positive results from 18 Phase 3 trials and strategic acquisitions of Verona Pharma and Cidara Therapeutics. Looking ahead, Merck anticipates 2026 worldwide sales between $65.5 and $67.0 billion and non-GAAP EPS between $5.00 and $5.15, reflecting a one-time charge related to the Cidara acquisition.

Key Takeaways

Full-year 2025 sales reached $65.0 billion, with KEYTRUDA sales at $31.7 billion.
WINREVAIR and CAPVAXIVE showed strong growth, contributing $1.4 billion and $759 million in sales, respectively.
GARDASIL sales declined 39% due to lower demand in China and Japan.
Merck received FDA Commissioner’s National Priority Vouchers for Enlicitide and Sacituzumab Tirumotecan, potentially expediting FDA review.
2026 sales are projected between $65.5 and $67.0 billion, with non-GAAP EPS between $5.00 and $5.15.

Analysis

Merck's results demonstrate the continued dominance of KEYTRUDA in the oncology space, but also highlight the importance of diversifying revenue streams with new product launches and strategic acquisitions. The decline in GARDASIL sales is a concern, indicating potential market saturation or increased competition in the HPV vaccine market. The acquisition of Verona Pharma and Cidara Therapeutics, along with the licensing agreement with Hengrui Pharma, signal Merck's commitment to expanding its pipeline and therapeutic areas. For investors, the positive late-stage trial results and FDA vouchers are encouraging, while the projected EPS for 2026, impacted by the Cidara acquisition, warrants close monitoring. Competitors in the oncology, cardiometabolic, and infectious disease spaces will be closely watching Merck's progress with its pipeline and newly acquired assets.

This post was automatically generated from an SEC 8-K filing.